Although CD8+ T-cell responses against these neoantigens were limited to a subset with a restricted TCR repertoire, mature dendritic cell vaccination using tumor-encoded amino acid-substituted (AAS) peptides revealed diverse CD8+ T-cell responses specific to neoantigens. The gene discussed is CD8A; the disease is neoplasm.